Top Markets
Coin of the day
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOBI
Clasificación en acciones #1377
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Precio por acción
$49.68
Capitalización bursátil
$17.25B
Cambio (1 día)
0.77%
Cambio (1 año)
72.50%
País
SE
Comercio Swedish Orphan Biovitrum AB (SOBI)

Categoría

Historial del precio de la acción de Swedish Orphan Biovitrum AB (SOBI)
Precio más alto de cierre: $49.98 el 2026-08-01

Precio más bajo de cierre: $7.09 el 2006-09-01
Historial del precio de la acción de Swedish Orphan Biovitrum AB desde 2006 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) 14.34%
2025 25.20%
2024 14.89%
2023 18.17%
2022 1.74%
2021 3.48%
2020 20.65%
2019 -22.43%
2018 59.16%
2017 20.01%
2016 -28.46%
2015 49.80%
2014 0.17%
2013 97.80%
2012 158.04%
2011 -61.87%
2010 51.76%
2009 45.44%
2008 -52.21%
2007 -31.43%
2006 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$59.08 64.74%
US
$184.45 47.77%
FR
$62.39 6.33%
IT
$113.04 53.61%
US
$0.63 -33.98%
HK